Fed. Circ. Revives Leo Psoriasis Drug Patent

Law360, New York (August 12, 2013, 8:21 PM EDT) -- The Federal Circuit on Monday reversed a U.S. Patent and Trademark Office decision invalidating a Leo Pharmaceutical Products Ltd. patent for a psoriasis treatment, ruling the office ignored "compelling" evidence that the patent should not have been found obvious.

When it reexamined the patent at the request of Leo's rival Galderma SA, the USPTO's Patent Trial and Appeal Board concluded that it would have been obvious in view of three older patents. However, the Federal Circuit said that those patents did not address the problems with...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.